



# Terbinafine Resistance of *Trichophyton* Clinical Isolates Caused by Specific Point Mutations in the Squalene Epoxidase Gene

Tsuyoshi Yamada,<sup>a,b</sup> Mari Maeda,<sup>a</sup> Mohamed Mahdi Alshahni,<sup>b</sup> Reiko Tanaka,<sup>c</sup> Takashi Yaguchi,<sup>c</sup> Olympia Bontems,<sup>d</sup> Karine Salamin,<sup>d</sup> Marina Fratti,<sup>d</sup> Michel Monod<sup>d</sup>

Teikyo University Institute of Medical Mycology, Tokyo, Japan<sup>a</sup>; General Medical Education and Research Center, Teikyo University, Tokyo, Japan<sup>b</sup>; Medical Mycology Research Center, Chiba University, Chiba, Japan<sup>c</sup>; Service de Dermatologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland<sup>d</sup>

**ABSTRACT** Terbinafine is one of the allylamine antifungal agents whose target is squalene epoxidase (SQLE). This agent has been extensively used in the therapy of dermatophyte infections. The incidence of patients with tinea pedis or unguium tolerant to terbinafine treatment prompted us to screen the terbinafine resistance of all *Trichophyton* clinical isolates from the laboratory of the Centre Hospitalier Universitaire Vaudois collected over a 3-year period and to identify their mechanism of resistance. Among 2,056 tested isolates, 17 (≈1%) showed reduced terbinafine susceptibility, and all of these were found to harbor SQLE gene alleles with different single point mutations, leading to single amino acid substitutions at one of four positions (Leu<sup>393</sup>, Phe<sup>397</sup>, Phe<sup>415</sup>, and His<sup>440</sup>) of the SQLE protein. Point mutations leading to the corresponding amino acid substitutions were introduced into the endogenous SQLE gene of a terbinafine-sensitive *Arthroderma vanbreuseghemii* (formerly *Trichophyton mentagrophytes*) strain. All of the generated *A. vanbreuseghemii* transformants expressing mutated SQLE proteins exhibited obvious terbinafine-resistant phenotypes compared to the phenotypes of the parent strain and of transformants expressing wild-type SQLE proteins. Nearly identical phenotypes were also observed in *A. vanbreuseghemii* transformants expressing mutant forms of *Trichophyton rubrum* SQLE proteins. Considering that the genome size of dermatophytes is about 22 Mb, the frequency of terbinafine-resistant clinical isolates was strikingly high. Increased exposure to antifungal drugs could favor the generation of resistant strains.

**KEYWORDS** dermatophytes, squalene epoxidase, terbinafine, *Trichophyton*, antifungal resistance, reverse genetics approach

Tinea pedis and tinea unguium are the most prevalent dermatophytoses. Both are generally caused by *Trichophyton rubrum* and *Trichophyton interdigitale*, with prevalences of approximately 80% and 20%, respectively (1). Control of tinea pedis and tinea unguium requires treatment with topical and/or oral fungicidal or fungistatic drugs (2). With some exceptions, antifungal drugs commonly used to treat dermatophytosis target the ergosterol biosynthetic pathway. Imidazoles such as econazole and triazoles such as itraconazole inhibit lanosterol 14- $\alpha$ -demethylase, which leads to the accumulation of sterol precursors and results in altered plasma membrane structure and function (3). In contrast, allylamines such as terbinafine are inhibitors of squalene epoxidase, an enzyme involved in the early steps of ergosterol biosynthesis (4). This inhibition results in the accumulation of squalene, which is toxic to fungi (5). Terbin-

Received 20 January 2017 Returned for modification 8 February 2017 Accepted 1 April 2017

Accepted manuscript posted online 17 April 2017

**Citation** Yamada T, Maeda M, Alshahni MM, Tanaka R, Yaguchi T, Bontems O, Salamin K, Fratti M, Monod M. 2017. Terbinafine resistance of *Trichophyton* clinical isolates caused by specific point mutations in the squalene epoxidase gene. *Antimicrob Agents Chemother* 61:e00115-17. <https://doi.org/10.1128/AAC.00115-17>.

**Copyright** © 2017 American Society for Microbiology. All Rights Reserved.

Address correspondence to Michel Monod, Michel.Monod@chuv.ch.

**TABLE 1** Phenotypic and genotypic characteristics of the clinical isolates obtained from patients with dermatophyte infections

Species and isolate no. <sup>a</sup>	Infection type	Growth with terbinafine <sup>b</sup>	Nucleotide substitution within the <i>SQL</i> E gene	Amino acid substitution	Terbinafine MIC ( $\mu$ g/ml)	Fold expression of <i>SQL</i> E (mean $\pm$ SD) <sup>d</sup>
<i>T. interdigitale</i>						
ATCC MYA-4439			None	None	0.00625	ND
<i>T. rubrum</i>						
CBS118892			None	None	ND <sup>c</sup>	1.08 $\pm$ 0.47
TIMM20083	Tinea pedis	+++	<sup>1177</sup> TTA $\rightarrow$ TTT	Leu393Phe	6.4	1.26 $\pm$ 0.48
TIMM20084	Tinea pedis	+++	<sup>1177</sup> TTA $\rightarrow$ TTT	Leu393Phe	3.2	0.67 $\pm$ 0.25
TIMM20093	Tinea pedis	+++	<sup>1177</sup> TTA $\rightarrow$ TTT	Leu393Phe	6.4	ND
TIMM20094	Tinea unguium	+++	<sup>1177</sup> TTA $\rightarrow$ TTT	Leu393Phe	6.4	ND
TIMM20088	Tinea unguium	+++	<sup>1177</sup> TTA $\rightarrow$ TCA	Leu393Ser	1.6	ND
TIMM20095	Tinea unguium	+++	<sup>1177</sup> TTA $\rightarrow$ TCA	Leu393Ser	ND	ND
TIMM20085	Tinea unguium	+++	<sup>1189</sup> TTC $\rightarrow$ TTA	Phe397Leu	3.2	ND
TIMM20086	Tinea unguium	+++	<sup>1189</sup> TTC $\rightarrow$ CTC	Phe397Leu	6.4	0.72 $\pm$ 0.29
TIMM20087	Tinea unguium	+++	<sup>1189</sup> TTC $\rightarrow$ TTA	Phe397Leu	ND	0.64 $\pm$ 0.27
TIMM20092	Tinea pedis	+++	<sup>1189</sup> TTC $\rightarrow$ CTC	Phe397Leu	>12.8	ND
TIMM20091	Tinea pedis	+++	<sup>1189</sup> TTC $\rightarrow$ ATC	Phe397Ile	0.8	ND
TIMM20097	Tinea unguium	+	<sup>1189</sup> TTC $\rightarrow$ GTC	Phe397Val	ND	ND
TIMM20090	Tinea unguium	+++	<sup>1305</sup> TTC $\rightarrow$ ATC	Phe415Ile	0.1	ND
TIMM20098	Tinea pedis	+	<sup>1305</sup> TTC $\rightarrow$ TCC	Phe415Ser	ND	ND
TIMM20082	Tinea unguium	+++	<sup>1305</sup> TTC $\rightarrow$ GTC	Phe415Val	0.4	ND
TIMM20089	Tinea unguium	+	<sup>1380</sup> CAT $\rightarrow$ TAT	His440Tyr	0.1	ND
<i>T. interdigitale</i>						
TIMM20096	Tinea unguium	+++	<sup>1189</sup> TTC $\rightarrow$ CTC	Phe397Leu	3.2	ND

<sup>a</sup>All the clinical isolates were obtained in Switzerland and deposited in the culture collection of Teikyo University Institute of Medical Mycology (TIMM).

<sup>b</sup>The growth ability of the clinical isolates on SDA containing 0.2  $\mu$ g/ml terbinafine is indicated as weak (+) to vigorous (+++).

<sup>c</sup>ND, not determined.

<sup>d</sup>Results represent expression levels from three independent real-time PCR experiments. Expression levels of *SQL*E genes were indicated as relative fold changes compared to the CT mean of the wild-type strain CBS118892 data.


afine has been found to be (as the drug of choice) efficacious for curing both tinea pedis and tinea unguium and is now used worldwide.

Although *T. rubrum* clinical isolates resistant to terbinafine are rarely described in the literature, therapeutic failure has been recorded in Lausanne (Switzerland) in patients with tinea pedis or onychomycosis. In these cases, the infectious agent was unambiguously identified as *T. rubrum*. To date, only two cases of terbinafine resistance have been investigated at the biochemical and DNA levels in *T. rubrum* clinical isolates from onychomycoses (6–9). Resistance was shown to be due to single point mutations in the gene encoding squalene epoxidase. Both mutations introduced missense substitutions (Leu393Phe in one case and Phe397Leu in the other), resulting in a more than 100-fold higher MIC (9, 10). Antifungal resistance in many fungi is also mediated by overexpression of genes encoding multidrug transporters (11–13). However, no resistance mediated by efflux pumps of the ATP-binding cassette (ABC) transporter family or by efflux pumps of the major facilitator family has yet been documented in dermatophyte clinical isolates.

Because of the incidence of patients with tinea pedis and tinea unguium insensitive to terbinafine treatment, the aims of this work are (i) to determine the frequency of terbinafine-resistant *Trichophyton* clinical isolates in a large screening of isolates from patients for whom a mycological analysis was performed at the Centre Hospitalier Universitaire Vaudois (CHUV) and (ii) to identify the mechanisms of resistance of dermatophytes insensitive to terbinafine.

## RESULTS

**Isolation of dermatophyte strains showing reduced susceptibility to terbinafine.** A total of 1,644 *T. rubrum* and 412 *T. interdigitale* clinical isolates, which were mainly collected from patients with tinea pedis or tinea unguium, were tested for growth ability on Sabouraud dextrose agar (SDA) containing 0.2  $\mu$ g/ml terbinafine. Only 16 *T. rubrum* and one *T. interdigitale* isolate grew on the medium (Table 1). To



**FIG 1** Agarose gel electrophoresis of the TRS-1 (lanes 1 to 4) and TRS-2 (lanes 5 to 8) regions from terbinafine-resistant *T. rubrum* clinical isolates with the same point mutation in the *SQL*E gene. (A) Strains with the replacement of Leu<sup>393</sup> with Phe in *SQL*E. Lanes 1 and 5, TIMM20083; lanes 2 and 6, TIMM20084; lanes 3 and 7, TIMM20093; lanes 4 and 8, TIMM20094. (B) Strains with the replacement of Phe<sup>397</sup> with Leu in the *SQL*E. Lanes 1 and 5, TIMM20085; lanes 2 and 6, TIMM20086; lanes 3 and 7, TIMM20087; lanes 4 and 8, TIMM20092. Leu<sup>397</sup> is encoded by TTA in TIMM20085 and TIMM20087 and by CTC in TIMM20086 and TIMM20092.

investigate further the reduced terbinafine susceptibility of such strains, their squalene epoxidase (*SQL*E) genes were amplified by PCR and sequenced. As shown in Table 1, the *SQL*E genes of all the strains were revealed to contain point mutations leading to amino acid substitutions at one of four amino acid positions (Leu<sup>393</sup>, Phe<sup>397</sup>, Phe<sup>415</sup>, and His<sup>440</sup>) within the *SQL*E protein, strongly suggesting that a structural change in the *SQL*E protein might be involved in the reduced susceptibility of these strains to terbinafine.

We used the length polymorphism of the tandem repetitive subelement 1 (TRS-1) and TRS-2 amplicons tentatively to differentiate *T. rubrum* resistant isolates carrying identical point mutations. The length polymorphism of TRS-1 allowed the differentiation of TIMM20083 and TIMM20093 from TIMM20084 and TIMM20094 (Fig. 1A). These four strains carried identical A-to-T substitutions at position 1179 of the open reading frame (ORF) of the *SQL*E gene, leading to the replacement of Leu<sup>393</sup> by Phe in the *SQL*E protein. The length polymorphism of TRS-2 allowed the differentiation of TIMM20086 from TIMM20092 (Fig. 1B). These two strains carried identical T-to-C substitutions in position 1189 of the open reading frame of the *SQL*E gene, leading to the replacement of Phe<sup>397</sup> by Leu in the *SQL*E protein. TIMM20085 and TIMM20087, which carried identical C-to-A substitutions at position 1191 of the open reading frame of the *SQL*E gene, could not be differentiated. Similar to TIMM20086 and TIMM20092, Phe<sup>397</sup> was replaced by Leu in the *SQL*E protein.

The MIC values, measured by the broth microdilution method, varied from one isolate to another and appeared to depend on the detected mutation (Table 1). While the MIC values were almost the same for all Leu<sup>393</sup>Phe mutants, substantial differences were observed between Phe<sup>397</sup>Leu mutants. In particular, TIMM20092 showed a higher terbinafine tolerance than the other two Phe<sup>397</sup>Leu mutants (TIMM20085 and TIMM20086). The MIC values of TIMM20095 (Leu<sup>393</sup>Ser), TIMM20087 (Phe<sup>397</sup>Leu), TIMM20097 (Phe<sup>397</sup>Val), and TIMM20098 (Phe<sup>415</sup>Ser) were not estimated because these isolates dramatically decreased their conidial productivity.

**Point mutations detected in the *SQL*E gene of resistant strains confer resistance to terbinafine.** We examined whether the single amino acid substitutions in the *SQL*E protein of the 17 *Trichophyton* isolates were involved in the terbinafine resistance phenotypes. Point mutations corresponding to the amino acid substitutions in these isolates were introduced into the endogenous *SQL*E gene of a terbinafine-sensitive dermatophyte strain by genetic manipulations. To enhance the generation of such mutations, *Arthroderma vanbreuseghemii* was used as a recipient organism, for which a variety of more efficient genetic manipulation tools have been developed than for *T. rubrum* and *T. interdigitale* (14). *A. vanbreuseghemii*, *T. rubrum*, and *T. interdigitale* *SQL*E


**TABLE 2** Plasmids used in this study

Plasmid	Description <sup>a</sup>	Source or reference
pAg1	Streamlined version of the binary vector pBIN19 containing sequences necessary for replication in <i>E. coli</i> and <i>A. tumefaciens</i> ( <i>oriV</i> and <i>trfA</i> ), <i>E. coli</i> neomycin phosphotransferase ( <i>nptII</i> ), and the transferable DNA (T-DNA) region, with a multiple cloning site within the T-DNA region	37
pAg1- <i>AbKu70</i> /T2	<i>AbKu70a</i> fragment (the 5' UTR of <i>AbKu70</i> gene; 2.49 kb), 5' FRT sequence, <i>P<sub>trpC</sub></i> (GenBank accession no. X02390), <i>nptII</i> , <i>T<sub>cgrA</sub></i> (AFUA_8G02750), <i>P<sub>ctrA</sub></i> (TERG_01401), <i>Pcflp</i> , <i>T<sub>trp1</sub></i> (M74901), <i>AbKu70b</i> fragment (the 3' UTR of <i>AbKu70</i> gene; 2.19 kb)	This study
pAg1- <i>AvSQLE</i> /T	<i>SQLEa</i> fragment (5'-UTR and ORF of the <i>AvSQLE</i> gene; about 3.88 kb), 5' FRT sequence, <i>P<sub>trpC</sub></i> , <i>nptII</i> , <i>T<sub>cgrA</sub></i> , <i>P<sub>ctrA</sub></i> , <i>Pcflp</i> , <i>T<sub>trp1</sub></i> , 3' FRT sequence, <i>SQLEb</i> fragment (the 3'-UTR of the <i>AvSQLE</i> gene; about 2.31 kb)	This study
pAg1- <i>mAvSQLE</i> /T series	<i>SQLEa</i> fragment (the 5'-UTR of <i>AvSQLE</i> gene and each mutated <i>AvSQLE</i> ORF leading to the Leu393Phe, Leu393Ser, Phe397Leu, Phe397Ile, Phe397Val, Phe415Ser, Phe415Val or His440Tyr substitution in <i>AvSQLE</i> ) (3.88kb), 5'-FRT sequence, <i>P<sub>trpC</sub></i> , <i>nptII</i> , <i>T<sub>cgrA</sub></i> , <i>P<sub>ctrA</sub></i> , <i>Pcflp</i> , <i>T<sub>trp1</sub></i> , 3'-FRT sequence, <i>SQLEb</i> fragment (the 3'-UTR of <i>AvSQLE</i> gene) (about 2.31kb)	This study
pAg1- <i>sSQLE</i> /T	<i>SQLEa</i> fragment (5' UTR of the <i>AvSQLE</i> gene and the <i>sSQLE</i> ORF encoding wild-type TrSQLE; 3.88kb), 5' FRT sequence, <i>P<sub>trpC</sub></i> , <i>nptII</i> , <i>T<sub>cgrA</sub></i> , <i>P<sub>ctrA</sub></i> , <i>Pcflp</i> , <i>T<sub>trp1</sub></i> , 3' FRT sequence, <i>SQLEb</i> fragment (the 3' UTR of the <i>AvSQLE</i> gene; 2.31 kb)	This study
pAg1- <i>msSQLE</i> /T series	<i>SQLEa</i> fragment (5' UTR of <i>AvSQLE</i> gene and each mutated <i>sSQLE</i> ORF leading to the Leu393Phe, Leu393Ser, Phe397Leu, Phe397Ile, Phe397Val, Phe415Ser, Phe415Val, or His440Tyr substitution in TrSQLE; 3.88kb), 5' FRT sequence, <i>P<sub>trpC</sub></i> , <i>nptII</i> , <i>T<sub>cgrA</sub></i> , <i>P<sub>ctrA</sub></i> , <i>Pcflp</i> , <i>T<sub>trp1</sub></i> , 3' FRT sequence, <i>SQLEb</i> fragment (the 3' UTR of the <i>AvSQLE</i> gene; about 2.31 kb)	This study


<sup>a</sup>ORF, open reading frame; *sSQLE*, synthetic *SQLE*.

genes each comprise a 1,532-bp ORF encoding 489 amino acids. The amino acid sequence of *A. vanbreuseghemii* SQLE (*AvSQLE*) is completely identical to that of *T. interdigitale* (GenBank accession number [EZF33561](#)). However, it differs in six amino acids at distinct positions (Val<sup>24</sup>, Thr<sup>52</sup>, Glu<sup>174</sup>, Asp<sup>352</sup>, Ala<sup>392</sup>, and Ile<sup>483</sup>) from that of *T. rubrum* SQLE (TrSQLE) (GenBank accession number [EGD89476](#)), with some potential impacts on the structure of mutated *AvSQLE* proteins expressed in *A. vanbreuseghemii*. Based on this possibility, expression of wild-type and mutated TrSQLE proteins in *A. vanbreuseghemii* was also investigated. The synthetic *SQLE* gene (designated *sSQLE*), which encodes the wild-type TrSQLE protein, and the *SQLE* gene alleles harboring point mutations leading to single amino acid substitutions in *SQLE* proteins were generated from the wild-type *AvSQLE* gene by overlap extension PCR. Four types of *AvSQLE*-targeting vectors harboring those alleles (Table 2) were constructed and introduced into the terbinafine-sensitive *A. vanbreuseghemii* strain 1062Av1401, according to the gene replacement strategy shown in Fig. 2A and B. Our initial attempt at transformation was unsuccessful, except for the production of transformants (named Av-FRT-1-3 and Tr-FRT-52-9, where FRT is FLP recombinase target) harboring the *AvSQLE* or *sSQLE* gene without any point mutation. However, subsequent attempts at transformation using these two clones as the recipient strains led to the successful production of clones harboring the mutated *SQLE* gene alleles, leading to the Leu393Phe, Leu393Ser, Phe397Ile, Phe397Leu, Phe397Val, Phe415Val, or His440Tyr substitution in *AvSQLE* and TrSQLE proteins (Fig. 2C). However, mutant strains harboring a Phe415Ser substitution could not be generated.

The growth properties of the obtained *A. vanbreuseghemii* transformants harboring the mutated *AvSQLE* or *sSQLE* gene on solid medium containing terbinafine were compared with growth of the parent strain 1062Av1401. The two clones, i.e., Av-FRT-1-3 and Tr-FRT-52-9, which harbor the wild-type *AvSQLE* or *sSQLE* gene, were used as the control strains. As shown in Fig. 3, 1062Av1401, Av-FRT-1-3, and Tr-FRT-52-9 were unable to grow on SDA containing 0.005  $\mu$ g/ml terbinafine, while all the clones harboring the mutated *SQLE* genes maintained growth activity. The MICs of terbinafine and itraconazole against these resistant clones were measured using the CLSI broth microdilution method (15). As shown in Table 3, clones that harbor the mutated *AvSQLE* and *sSQLE* genes were 8- to 512-fold less susceptible to terbinafine, respectively, than their respective control strains, demonstrating that the terbinafine tolerance of the clinical *Trichophyton* strains was conferred by single amino acid substitutions in the



**FIG 2** Introduction of point mutations into the endogenous *SQLE* gene of *A. vanbreuseghemii* by gene replacement strategy. (A) Schematic representation of a series of binary *AvSQLE*-targeting vectors. DNA fragments (*SQLEa* and *SQLEb*) containing the 5' UTR of the *AvSQLE* gene and the open reading frames encoding wild-type and mutated *A. vanbreuseghemii* or *T. rubrum* *SQLE* proteins (ORF\*) as well as the 3' UTR of the *AvSQLE* gene were subcloned into the pAg1-*AbKu70/T2* upstream (*SpeI*/*Apal*) and downstream (*Bam*HI/*Kpn*I) of the PcFLP/FRT module, respectively (Table 2 and Fig. S1). The *nptII* cassette is composed of *Aspergillus nidulans* *trpC* promoter (*P<sub>trpC</sub>*), *E. coli* neomycin phosphotransferase gene (*nptII*), and the *A. fumigatus* *cgrA* terminator (*T<sub>cgrA</sub>*). *P<sub>ctr4</sub>*, *T. rubrum* *ctr4* promoter (34); *Pcflp*, the synthetic *flp* gene with *Penicillium chrysogenum*-optimized codon usage (35); *T<sub>trp1</sub>*, *Cryptococcus neoformans* *trp1* terminator (36); FRT, FLP recombinase target sequence; LB and RB, left and right borders, respectively; A, *Apal*; B, *Bam*HI; C, *Clal*; K, *Kpn*I; Sc, *Sac*I; Sh, *Sph*I; Sp, *Spe*I. (B) Schematic representation of the *AvSQLE* locus before and after homologous recombination and excision of the PcFLP/FRT module. Site-specific recombination between the flanking FRT sequences was induced by conditional expression of *Pcflp* after transformation. All the internal *Bam*HI sites contained in the amplified fragments were inactivated by overlap extension PCR. (C) Southern blotting. Aliquots of approximately 10  $\mu$ g of total DNA from each mutant strain were digested with *Bam*HI and separated by electrophoresis on 0.8% (wt/vol) agarose gels. 1062Av1401 indicates the parent strain. Lane 1, Av-FRT-1-3 (*AvSQLE*'s control); lane 2, Av-538A (Leu393Phe); lane 3, Av-1-3 (Leu393Ser); lane 4, Av-S714J6 (Phe397Leu); lane 5, Av-7-5 (Phe397Ile); lane 6, Av-4-1 (Phe397Val); lane 7, Av-S28M (Phe415Val); lane 8, Av-2-4 (His440Tyr); lane 9, Tr-FRT-52-9 (*TrSQLE*'s control); lane 10, Tr-T31C (Leu393Phe); lane 11, Tr-2-3 (Leu393Ser); lane 12, Tr-T719J (Phe397Leu); lane 13, Tr-4-1 (Phe397Ile); lane 14, Tr-75-6 (Phe397Val); lane 15, Tr-T4B (Phe415Val); lane 16, Tr-2-1 (His440Tyr). A 566-bp fragment of the *AvSQLE* gene was amplified by PCR with the primer pair *AvSQLE*-F23 and *AvSQLE*-R21 (Table 4) and used as a hybridization probe. DNA standard fragment sizes are shown on the left.



**FIG 3** The growth properties of *A. vanbreuseghemii* transformants expressing mutated AvSQLE and TrSQLE proteins on solid terbinafine-containing medium. Aliquots of 10  $\mu$ l of conidial suspensions containing  $1 \times 10^5$  cells were spotted onto SDA with (+) or without (-) 0.005  $\mu$ g/ml terbinafine and incubated at 28°C for 3 days. Bar, 1.0 cm.


SQLQ protein. Noteworthy clones with the Phe397Val substitution showed reduced growth rates (Fig. 4A). This finding has correlates with the observation that the clinical isolate TIMM20097 harboring the Phe397Val substitution grew slowly compared to growth of the wild-type *T. rubrum* and the isolate TIMM20085 harboring the Phe397Leu substitution (Fig. 4B). Similarly, the isolate TIMM20098 harboring the Phe415Ser substitution showed much more retarded growth than the wild-type *T. rubrum* and the isolate TIMM20082 harboring the Phe415Val substitution.

No apparent difference was observed in the susceptibilities to itraconazole between transformants harboring the mutated *SQLQ* genes and control strains (Table 3).

**TABLE 3** Susceptibilities to terbinafine and itraconazole of *A. vanbreuseghemii* transformants expressing mutated forms of the *SQLQ* gene and corresponding expression levels

Species and strain	Amino acid substitution	MIC ( $\mu$ g/ml)		Fold expression of <i>SQLQ</i> (mean $\pm$ SD) <sup>a</sup>
		Terbinafine	Itraconazole	
<i>T. interdigitale</i>				
ATCC MYA-4439	None	0.00625	0.12	ND
<i>A. vanbreuseghemii</i>				
1062Av1401	None	0.0125	0.06	1.02 $\pm$ 0.24
Av-FRT-1-3	None	0.00625	0.12	1.28 $\pm$ 0.06
Av-S38A	Leu393Phe	1.6	0.12	1.08 $\pm$ 0.11
Av-1-3	Leu393Ser	0.4	0.12	ND
Av-S714J6	Phe397Leu	3.2	0.12	1.37 $\pm$ 0.11
Av-7-5	Phe397Ile	1.6	0.06	ND
Av-S28 M	Phe415Val	0.4	0.12	ND
Av-2-4	His440Tyr	0.2	0.12	ND
<i>T. rubrum</i>				
Tr-FRT-52-9	None	0.00625	0.06	1.27 $\pm$ 0.14
Tr-T31C	Leu393Phe	3.2	0.12	1.63 $\pm$ 0.18
Tr-2-3	Leu393Ser	0.4	0.06	ND
Tr-T719J	Phe397Leu	3.2	0.06	1.35 $\pm$ 0.16
Tr-4-1	Phe397Ile	1.6	0.06	ND
Tr-T4B	Phe415Val	0.4	0.12	ND
Tr-2-1	His440Tyr	0.05	0.25	ND

<sup>a</sup>Results are from three independent real-time PCR experiments. ND, not determined. Expression levels of *SQLQ* genes are indicated as relative fold changes compared to the CT mean of the parent strain 1062Av1401 data.



**FIG 4** The growth properties of *A. vanbreuseghemii* transformants with the substitution Phe<sup>397</sup>Val in the *SQL*E protein (A) and *T. rubrum* clinical isolates harboring the Phe397Val or Phe415Ser substitution in the *SQL*E protein (TIMM20097 or TIMM20098, respectively) in comparison to a Leu or Val residue, respectively (TIMM20085 and TIMM20082, respectively) (B) on solid medium. Aliquots of 10  $\mu$ l of conidial suspensions containing  $1 \times 10^5$  cells were spotted onto SDA and incubated at 28°C for 4 days (A) or 5 days (B). The wild-type *T. rubrum* CBS118892 was used as control. Bar, 1.0 cm.

**Comparative analysis of the *SQL*E gene expression levels among terbinafine-resistant dermatophyte strains.** To examine whether the resistance shown by *A. vanbreuseghemii* transformants was due to a point mutation in their *SQL*E genes or to different expression levels of polymorphic alleles in the heterologous host, quantitative real-time reverse transcription-PCR (qRT-PCR) was conducted. The *SQL*E gene expression levels in four *T. rubrum* clinical isolates and six *A. vanbreuseghemii* transformants, harboring the corresponding mutated *SQL*E genes or the wild-type alleles, were evaluated. Relative *SQL*E gene expression levels in the two control strains (Av-FRT-1-3 and Tr-FRT-52-9) did not show a significant difference from the level of their parent strain 1062Av1401 (Table 3). Likewise, no statistically significant differences in the *SQL*E gene expression levels were found between four *A. vanbreuseghemii* transformants and their respective parent strains, Av-FRT-1-3 and Tr-FRT-52-9 (Table 3). These results clearly indicate that resistance to terbinafine in *A. vanbreuseghemii* transformants was due to the respective point mutations. In addition, no statistically significant differences in *SQL*E gene expression levels were found between the four *T. rubrum* clinical isolates and the wild-type *T. rubrum* strain CBS118892 (Table 1).

## DISCUSSION

**Specific point mutations in squalene epoxidase genes causing terbinafine resistance.** Drug resistance of fungi has been increasing at an alarming rate over the past few decades. An understanding of the underlying molecular mechanisms is indispensable for successful therapies. In the current study, all 17 terbinafine-resistant *Trichophyton* clinical isolates were revealed to harbor squalene epoxidase (*SQL*E) gene alleles with point mutations, leading to amino acid substitutions at one of four amino acid positions (Leu<sup>393</sup>, Phe<sup>397</sup>, Phe<sup>415</sup>, and His<sup>440</sup>) within the *SQL*E protein. The single amino acid substitutions Leu393Phe and Phe397Leu in the *SQL*E protein have been

previously reported, marking the first two cases of terbinafine-resistant *T. rubrum* strains isolated from patients (6, 9).

In a previous study, mutants of *Saccharomyces cerevisiae* resistant to terbinafine were generated by chemical, UV, and PCR-based mutagenesis, and molecular analysis revealed point mutations in the *SQL*E gene, leading to amino acid substitutions at one of five amino acid positions, Leu<sup>231</sup>, Phe<sup>402</sup>, Phe<sup>420</sup>, Pro<sup>430</sup>, and Phe<sup>433</sup>, in the *SQL*E protein (16). The residues Phe<sup>402</sup> and Phe<sup>420</sup> in *S. cerevisiae* *SQL*E correspond to Phe<sup>397</sup> and Phe<sup>415</sup> in *T. rubrum* *SQL*E, respectively. No amino acid substitutions equivalent to Leu<sup>231</sup>, Pro<sup>430</sup>, and Phe<sup>433</sup> in *S. cerevisiae* *SQL*E were identified in the 17 terbinafine-resistant *Trichophyton* clinical isolates of the present study. Amino acid substitutions corresponding to Phe<sup>397</sup>Leu in the *Trichophyton* *SQL*E protein were also found in equivalent positions in the *SQL*E protein of *Aspergillus fumigatus* and *Aspergillus nidulans* terbinafine-resistant strains (17). Accordingly, point mutations at one of a few sites in the *SQL*E gene confer resistance to terbinafine in different fungi.

Identification of precise amino acid substitutions responsible for resistance to drugs is helpful in the determination of the interaction between the drugs and their targets. The atomic three-dimensional (3D) modeling of the *S. cerevisiae* *SQL*E protein was built based on previously available experimental findings, and, furthermore, it would screen the detailed amino acids critical for binding terbinafine to the enzyme (18). Among the 50 amino acids screened in that study, Phe<sup>402</sup>, Cys<sup>416</sup>, Phe<sup>417</sup>, Phe<sup>420</sup>, Tyr<sup>90</sup>, and Val<sup>92</sup> seem to interact especially strongly with this agent. Similar to the *S. cerevisiae* *SQL*E protein, all of the amino acid substitutions found in the *SQL*E protein of the terbinafine-resistant *Trichophyton* clinical isolates reported in the present study and previously (6, 9) were also localized in the C-terminal region of *SQL*E. However, the *A. vanbreuseghemii* transformants carrying amino acid substitutions at Phe<sup>415</sup>, equivalent to Phe<sup>420</sup> in the *S. cerevisiae* *SQL*E, were 4- to 8-fold more susceptible to terbinafine than those carrying amino acid substitutions at Leu<sup>393</sup> and Phe<sup>397</sup>, equivalent to Leu<sup>398</sup> and Phe<sup>402</sup> in the *S. cerevisiae* *SQL*E protein (Table 3). Hence, there is a possibility that together with Phe<sup>397</sup>, Leu<sup>393</sup> rather than Phe<sup>415</sup> would make greater contributions to the *SQL*E-terbinafine firm contacts in *Trichophyton* species. In addition, His<sup>440</sup> in the *Trichophyton* *SQL*E protein was shown to confer resistance to terbinafine for the first time in the present study. However, there is a valine (Val<sup>447</sup>) in the equivalent position of the *S. cerevisiae* *SQL*E protein, which was not screened by the 3D modeling study as an amino acid critical for binding terbinafine to the enzyme. These results suggest a subtle conformational difference of the terbinafine binding pocket within the enzyme between *S. cerevisiae* and *Trichophyton* *SQL*E proteins, possibly leading to the difference in their susceptibilities to this agent. Alternatively, an amino acid substitution may cause conformational changes in the enzyme that result in reduced drug affinity.

**Transfer of terbinafine resistance from one isolate to another.** To investigate the relationship between these amino acid substitutions and terbinafine tolerance, point mutations leading to several amino acid substitutions found in the *SQL*E protein of the *Trichophyton* clinical isolates were introduced into the endogenous *SQL*E gene of the dermatophyte *Arthroderma vanbreuseghemii* using genetic manipulation tools. As shown in Table 3, all of the *A. vanbreuseghemii* transformants expressing mutated *SQL*E proteins showed significant reductions in susceptibilities to terbinafine, demonstrating that the amino acid substitutions in the *SQL*E protein are a major cause of the terbinafine resistance in *Trichophyton* clinical isolates. Interestingly, transformants with the Phe<sup>397</sup>Val substitution displayed retarded growth (Fig. 4A). The clinical isolates TIMM20097 and TIMM20098 harboring the Phe<sup>397</sup>Val and Phe<sup>415</sup>Ser substitutions, respectively, also grew slowly compared to growth of the wild-type *T. rubrum* and the isolates TIMM20085 and TIMM20082 harboring the Phe<sup>397</sup>Leu and Phe<sup>415</sup>Val substitutions, respectively (Fig. 4B). These results suggest the possibility that the Phe<sup>397</sup>Val and Phe<sup>415</sup>Ser substitutions in the *SQL*E protein affect both the susceptibility to terbinafine and the squalene epoxidase activity. The report of fluconazole resistance in *Candida albicans* associated with reduced affinity of sterol 14- $\alpha$ -demethylase (target of



fluconazole) supports this hypothesis (19). Similarly, the growth of TIMM20098 was more retarded than that of TIMM20097 (Fig. 4B). This may explain why *A. vanbreuseghemii* transformants harboring the Phe415Ser substitution could not be successfully generated.

The discrepancy in terbinafine tolerance of our clinical isolates with the same Phe397Leu mutation, particularly TIMM20092 displaying higher tolerance, could be explained by additional mechanisms of resistance (Table 1). This hypothesis is supported by the abundant work on resistance to azole antifungal agents in *Candida albicans*. The fungal target of these agents is a cytochrome P450 encoded by the gene *ERG11*. Azole resistance of clinical isolates of *C. albicans* was mediated by various mechanisms, including missense mutations in *ERG11* and overexpression of genes encoding multidrug transporters, and combined effects of such mechanisms were observed in the same azole-resistant clinical isolate (20). It is possible that overexpression of genes coding for efflux pumps are also involved in terbinafine tolerance in some of our clinical isolates. Moreover, disruption of a multidrug transporter in *T. rubrum* resulted in an increased sensitivity to terbinafine among various tested antifungal compounds, which was 2-fold higher than that of the nonmutated strains cloned (21).

Selectable markers used in site-directed mutagenesis may also have effects on the susceptibility of generated mutants. A recent study on succinate dehydrogenase (Sdh), the primary molecular target of the novel antifungal agent ME1111, showed that the selectable marker cassette harboring the *E. coli* hygromycin B phosphotransferase gene could increase the susceptibility to the drug (22). The finding was evidenced by the fact that the generated control strains harboring the wild-type gene and the selectable marker cassette were more susceptible to ME1111 than the recipient host strain or reference strain. Hence, there is a possibility that the selectable marker, which was retained in the downstream region of the ORFs of each subunit gene, could confer reduced expression of such genes. To obviate the possibility, the point mutations in the present study were introduced into the endogenous *SQL*E gene of *A. vanbreuseghemii* using an FLP recombinase-mediated site-specific recombination system derived from *S. cerevisiae* (Fig. 2A and B). Following transformation of a recipient strain using each *SQL*E-targeting vector, the selectable marker (*E. coli* neomycin phosphotransferase gene) cassette was excised from the *SQL*E locus in the transformants by FLP recombinase-mediated site-specific recombination between the flanking FRT sequences. Nevertheless, an FRT site remained between the coding sequence of the gene and its downstream region. The FRT sequence is an inverted repeat and thus may affect transcription, mRNA secondary structure, and transcript stability. However, differences in transcription levels of the target gene with and without the added FRT sequence were found to be not statistically significant (Table 3). Moreover, as shown in Table 3, the generated marker-free control strains (Av-FRT-1-3 and Tr-FRT-52-9) showed susceptibilities to terbinafine and itraconazole that are nearly identical to those in the parent strain (1062Av1401) and the reference strain (*T. interdigitale* ATCC MYA-4439). The inserted wild-type gene could serve as a proper control for comparison with the mutated alleles.

**High frequency of terbinafine-resistant isolates.** The frequency of our terbinafine-resistant clinical isolates of about 1% is strikingly high, considering that the average size of genomes of dermatophytes is about 22 Mb (23). The various sizes of the amplicons obtained by specifically amplifying subrepeat elements in the ribosomal DNA nontranscribed spacer attested that different isolates with identical mutations did not belong to the same strain. Therefore, we could exclude the possibility of the propagation of a particular resistant strain in several patients. We also excluded the possibility that resistance was developed during our screening on SDA containing terbinafine for two reasons. (i) *Trichophyton* isolates were from patients with tinea pedis and/or onychomycosis who did not respond to terbinafine treatment. In three cases where a remaining portion of the sample was stored, the *SQL*E gene could be amplified by targeting total DNA extracted from nails, which was found to harbor a mutation identical to that identified in cultured *Trichophyton* (data not shown). (ii) The development of resistance

to terbinafine in *T. rubrum* was found to occur at a rare frequency *in vitro* (10). Moreover, no resistant *T. rubrum* strain was generated from a terbinafine-sensitive strain used as a negative control, which was always added with a terbinafine-resistant strain as a positive control in each test plate during the screening procedure.

To explain this high frequency of terbinafine-resistant strains, it should be considered that treatments with terbinafine involve a prolonged exposure to the antifungal drug, which could favor the selection of resistant strains. This hypothesis is supported by the finding that fluconazole resistance in *C. albicans* is correlated with the total dose of fluconazole administered to patients (24). The emergence of *C. albicans* strains that are less susceptible to this antifungal agent is favored by the uptake of a total dose of fluconazole of more than 5 g (24). Retrospective analysis of the follow-up of patients revealed that 8 of the 17 patients harboring a terbinafine-resistant *Trichophyton* isolate had already been treated with terbinafine when the skin and/or nail sample was sent to the laboratory for mycological analysis. One patient was apparently not pretreated. Complete data were not available for eight patients. Prospective studies would be of interest to confirm the possible emergence of resistant strains during long-term treatment.

## MATERIALS AND METHODS

**Strains and medium.** *Trichophyton interdigitale* ATCC MYA-4439 and *T. rubrum* CBS118892 were obtained from the American Type Culture Collection (Manassas, VA) or CBS-KNAW Culture Collections (Utrecht, Netherlands). *Arthroderma vanbreuseghemii* (formerly *T. mentagrophytes*) 1062Av1401 (25), which lacks a homolog of the human *Ku80* (26), was used as a recipient strain for genetic manipulation. Microconidium formation was induced at 28°C using modified 1/10 Sabouraud dextrose agar (SDA) (27) supplemented with 500 µg/ml cycloheximide (Wako Chemical) and 50 µg/ml chloramphenicol (Sigma-Aldrich). *Agrobacterium tumefaciens* EHA105 (28) was maintained as previously described (29). *Escherichia coli* DH5α (Nippon Gene) was used for molecular cloning.

**Screening of *Trichophyton* isolates resistant to terbinafine.** Over a 3-year period (2013 to 2016), 1,644 *T. rubrum* and 412 *T. interdigitale* isolates were obtained from clinical samples sent to the CHUV for mycological analysis. The samples were mainly collected from patients with tinea pedis or tinea unguium. All clinical isolates were tested for fungal growth on SDA containing 0.2 µg/ml terbinafine, a quantity equivalent to twice that of the MIC for *T. rubrum* and *T. interdigitale* under these conditions (30). Examination of fungal growth was performed after 7, 10, and 14 days. Growing strains were kept and stored in Lausanne and Tokyo in SD broth supplemented with glycerol and dimethyl sulfoxide (DMSO) at -80°C pending further analysis. Isolated terbinafine-resistant strains were deposited in the culture collection of the Teikyo University Institute of Medical Mycology (TIMM) under the identification numbers given in Table 1.

***Trichophyton* total DNA extraction and *SQL*E gene analysis.** *Trichophyton* total DNA was extracted from fresh fungal cultures on SD agar medium and nail samples as previously described using a DNeasy Plant minikit (Qiagen) (31). A diameter of approximately 0.5 cm of growing mycelium was used. Before DNA extraction, nail fragments (20 to 100 mg) were incubated overnight in 500 µl of sodium sulfide dissolving solution (10% [wt/vol] Na<sub>2</sub>S, 25% [vol/vol] ethanol). After centrifugation at 8,000 × *g* for 2 min, the sample precipitate containing fungal elements was washed twice with distilled water. The *SQL*E gene of the terbinafine-resistant clinical isolates was amplified by PCR with High Fidelity DNA Polymerase (Roche Diagnostics), the primer pair TrSQL-E-F1 and TrSQL-E-R1, and chromosomal DNA as the template. Nucleotide sequences of these primers are shown in Table 4.

***Trichophyton rubrum* strain typing.** Strain typing based on the length of the parts containing the tandem repetitive subelements (TRSs), TRS-1 and TRS-2, in nontranscribed spacers of ribosomal DNA (ribosomal DNA intergenic spacer regions) was performed as described by Jackson et al. (32). The primer pair TrNTSF-2 and TrNTSR-4 and the pair TrNTSC-1 and TrNTSR-1 were used to amplify the TRS-1 and the TRS-2 regions, respectively (32). Strains were characterized by the size of both TRS-1 and TRS-2 amplicons, which are polymorphic for length.

**Construction of transformation vectors harboring wild-type and mutated *SQL*E.** Genomic data of the *SQL*E locus that shares homology with the *T. rubrum* *SQL*E gene (*TrSQL*E) (GenBank accession number [TERG\\_05717](#)) were identified in *A. vanbreuseghemii* based on GenBank accession number [AB690298](#) and our private draft genome of the strain TIMM2789. *A. vanbreuseghemii* *SQL*E (designated AvSQL-E) differs in six amino acids at distinct positions (Val<sup>24</sup>, Thr<sup>52</sup>, Glu<sup>174</sup>, Asp<sup>352</sup>, Ala<sup>392</sup>, and Ile<sup>483</sup>) from TrSQL-E (GenBank accession number [EGD89476](#)). To generate the *SQL*E ORF fragment encoding the wild-type TrSQL-E protein, six point mutations were introduced into the AvSQL-E gene by overlap extension PCR with the corresponding six pairs of primers (listed in Table 4); the resultant fragment was designated sSQL-E (where *s* indicates synthetic gene). The *SQL*E gene alleles harboring point mutations leading to Leu393Phe, Leu393Ser, Phe397Leu, Phe397Ile, Phe397Val, Phe415Ser, Phe415Val, or His440Tyr in AvSQL-E and TrSQL-E were also generated from the wild-type AvSQL-E gene by overlap extension PCR with the corresponding pair of primers (listed in Table 4). All the amplified fragments were sequenced to verify the introduction of correct nucleotide substitutions at the targeted sites.

To construct a series of AvSQL-E locus-targeting binary vectors, two types of DNA fragments were amplified by PCR; the SQL-Ea fragment contained the 5' untranslated region (UTR) of the AvSQL-E gene

**TABLE 4** PCR primers used in this study

Purpose	Primer	Sequence (5'–3') <sup>b</sup>	Note
Amplification of <i>SQLE</i> genes for qRT-PCR	qRT_erg1_2-F qRT_erg1_2-R qRT_erg(Tr)1_2-F	CCAGACTGATGGCAAGCAAGA ATAAGCTCCAGGCCCCAGAA CCAGACTGATGGCAAACAAGA	
Amplification of <i>SQLE</i> genes from clinical isolates	TrSQLE-F1 TrSQLE-R1	ATGGTTGTAGAGGCTCCTCCC CTAGCTTTGAAGTTCGGCAAA	
Amplification of the DNA fragments containing the 5' UTR of <i>AvSQLE</i> and the <i>SQLE</i> ORF	AvSQLE-F15/Spel AvSQLE-R23/ApaI	TCACGAAGCTA <b>ACTAGT</b> ACCTGAAAGATGAC AAAAAGGCCCCCTAGCTTTGAAGTTCGGCAATA	Inactivation of the KpnI site
Amplification of the 3' UTR fragment of <i>AvSQLE</i>	AvSQLE-F13/BamHI AvSQLE-R16/KpnI	CAAGGATCCACAGATAGGCTTATCTCTAGCTCT CAGGGTACCTCCGTTCAATAGTCAACGAACGTCTCG	
Generation of the <i>sSQLE</i> ORF encoding wild-type TrSQLE <sup>a</sup>	AvSQLE-F21 AvSQLE-R18 AvSQLE-F22 AvSQLE-R19 AvSQLE-F23 AvSQLE-R20 AvSQLE-F24 AvSQLE-R21 AvSQLE-F25 AvSQLE-R22 AvSQLE-F26 AvSQLE-R24	TCCGCGAAGCCCAAGGTATACCGCAGCAGAA TTCGTCGCGGTAT <b>ACTT</b> GGGCTTCGCGGA GGCATTGCTGGATGT <b>AC</b> GCTGGCCGTTGCGTT AACGCAACGGCCAGCGT <b>TACATCC</b> AGCAATGCC TCCACGCACACAGGGG <b>AG</b> GTCCTTGGAGTTCAATG CATTGAACTCCAAGGAC <b>TCC</b> CTGTGTGCGTGGA ATGTCGTTCTCCTCCGG <b>GATCTACTT</b> AGTCCAGA TCTGGACTAAGTAGAT <b>CCCG</b> AGGAGAACGACAT TCAATATTCTTCC <b>AGC</b> CTTATACTCTATATTC GAATATAGAGTATAAG <b>GC</b> TGGGCAAGAATATTGA GGTCATCCTTCTTTC <b>AT</b> ATTTGCCGAACCT AAGTTCGGCAAA <b>TAT</b> GAAAGGAAGGATGACC	Ala24Val Ala52Thr Asp174Glu Asn352Asp, hybridization probe Ser392Ala Val483Ile
Generation of point mutations in <i>AvSQLE</i> and TrSQLE <sup>a</sup>	AvSQLE-F27 AvSQLE-R27 AvSQLE-F29 AvSQLE-R29 AvSQLE-F35 AvSQLE-R35 AvSQLE-F36 AvSQLE-R36 AvSQLE-F28 AvSQLE-R28 AvSQLE-F31 AvSQLE-R31 AvSQLE-F30 AvSQLE-R30 AvSE-F37 AvSE-R37 AvSQLE-F14 AvSQLE-R8 AvSQLE-F29 AvSQLE-R29	TTGCCAGTCCT <b>TCTACT</b> CTATATT AATATAGAGT <b>AGA</b> AAGGACTGGGCAA TTCTTGCC <b>AGCCTTCTACT</b> CTATATT AATATAGAGT <b>AGAAGGCCT</b> GGGCAAGAA TTGCCAGTCCT <b>CATACT</b> CTATATT AATATAGAGT <b>AGG</b> AAGGACTGGGCAA TTCTTGCC <b>AGGCCTCATACT</b> CTATATT AATATAGAGT <b>AGG</b> CTGGGCAAGAA TACTCTATATT <b>AGCCG</b> CTGGTG CACCAGCG <b>CTA</b> ATATAGAGTA TACTCTATA <b>AT</b> CGCCGCTGGTG CACCAGCG <b>CGATT</b> ATAGAGTA TACTCTAT <b>AGT</b> CGCCGCTGGTG CACCAGCG <b>CGACT</b> ATAGAGTA GGCTGCTT <b>CAGG</b> TATCCCACTGGACTTATA TATAAGTCCAAGT <b>TGG</b> AATACCTGAAGCAGCC GGCTGCTT <b>CAGG</b> TAT <b>G</b> TCCACTGGACTTATA TATAAGTCCAAGT <b>TGG</b> ACATACCTGAAGCAGCC CCTTGGT <b>CTATT</b> ACGATATTTTACTCCGTAGCC GGTACTCGGAGTAA <b>AAATAT</b> CGTAATAGAACCAAGG	Leu393Phe ( <i>AvSQLE</i> ) Leu393Phe ( <i>TrSQLE</i> ) Leu393Ser ( <i>AvSQLE</i> ) Leu393Ser ( <i>TrSQLE</i> ) Phe397Leu (both <i>SQLE</i> proteins) Phe397Ile (both <i>SQLE</i> proteins) Phe397Val (both <i>SQLE</i> proteins) Phe415Ser (both <i>SQLE</i> proteins) Phe415Val (both <i>SQLE</i> proteins) His440Tyr (both <i>SQLE</i> proteins)

<sup>a</sup>Introduction of nucleotide substitutions into *SQLE* genes by overlap extension PCR.

<sup>b</sup>Restriction sites are underlined, and substitutions are in boldface.

and each *SQLE* ORF, and the *SQLE*b fragment contained the 3' UTR of the *AvSQLE* gene (Fig. 2A). Each fragment was doubly digested with the *Spel*/*ApaI* or the *Bam*HI/*KpnI* enzymes, respectively, and subsequently subcloned into the binary vector pAg1-*AbKu70*/T2 (Table 2; see Fig. S1 in the supplemental material), resulting in the replacement of the 5' UTR and 3' UTR fragments of the *Arthroderma benhamiae* *Ku70* gene (ARB\_06096) within the vector. Depending on the *SQLE* ORF contained in the *SQLE*a fragment, four types of vectors were generated: pAg1-*AvSQLE*/T and pAg1-*sSQLE*/T harboring the *AvSQLE* ORF and the *sSQLE* ORF encoding the wild-type TrSQLE protein, respectively, and the pAg1-*mAvSQLE*/T and pAg1-*msSQLE*/T (where *m* indicates mutated gene constructs) series harboring the ORF of each mutated *SQLE* allele, which contained a point mutation leading to the Leu393Phe, Leu393Ser, Phe397Leu, Phe397Ile, Phe397Val, Phe415Ser, Phe415Val, or His440Tyr substitution in *AvSQLE* and TrSQLE proteins, respectively (Table 2).

The PCRs were performed using PrimeSTAR HS DNA polymerase or Extaq DNA polymerase (TaKaRa Bio). If necessary, the amplified fragments were gel purified with a QIAEX II gel extraction kit (Qiagen). All the internal *ApaI*, *Bam*HI, *KpnI*, and *Spel* sites contained in the amplified fragments were inactivated by overlap extension PCR with a corresponding pair of primers (Table S1).

**Fungal genetic transformation.** *A. vanbreuseghemii* 1062Av1401 was transformed by the *A. tumefaciens*-mediated transformation (ATMT) method as described previously (29). After cocultiva-

tion, nylon membranes were transferred onto SDA containing 250  $\mu\text{g/ml}$  G418 (Sigma-Aldrich) and 10  $\mu\text{M}$   $\text{CuSO}_4 \cdot 7\text{H}_2\text{O}$ , and overlaid with 10 ml of SDA supplemented with the same concentration of G418 and  $\text{CuSO}_4 \cdot 7\text{H}_2\text{O}$ . The plates were further overlaid after 48 h with 10 ml of SDA containing 350  $\mu\text{g/ml}$  G418 and 10  $\mu\text{M}$   $\text{CuSO}_4 \cdot 7\text{H}_2\text{O}$  and then incubated for 4 to 5 days. The colonies regenerating on the selective medium were considered putative G418-resistant clones and transferred onto solid morpholinepropanesulfonic acid (MOPS)-buffered RPMI 1640 medium (RPMI 1640A) supplemented with 500  $\mu\text{g/ml}$  cycloheximide, 50  $\mu\text{g/ml}$  chloramphenicol, 200  $\mu\text{g/ml}$  cefotaxime sodium (Sanofi-Aventis) (if necessary), and 20  $\mu\text{M}$  bathocuproine disulfonate (BCS) (Dojindo Laboratories) and passaged several times. The *T. rubrum ctr4* promoter ( $P_{ctr4}$ ) is a conditional promoter that is repressed in the presence of copper. Chelation of copper by bathocuproine sulfate activates the  $P_{ctr4}$ , leading to the induction of *Penicillium chrysogenum flp* (*Pcflp*) gene expression. Expression of PcFLP recombinase leads to excision of the selectable marker via PcFLP-mediated site-specific recombination between the flanking FRT sequences.

**Screening of the desired transformants.** The desired transformants were finally screened by PCR, Southern blotting analyses, and nucleotide sequencing. Total DNA was extracted according to a method described previously (29). Aliquots of 50 to 100 ng of the total DNA were used as templates in the PCRs. For Southern blotting, aliquots of approximately 10  $\mu\text{g}$  of the total DNA were digested with an appropriate restriction enzyme, separated by electrophoresis on 0.8% (wt/vol) agarose gels, and transferred onto Hybond- $\text{N}^+$  membranes (GE Healthcare Ltd.). Southern hybridization was performed using an ECL Direct Nucleic Acid Labeling and Detection System (GE Healthcare Ltd.) according to the manufacturer's instructions.

**Drug susceptibility testing.** MICs were determined according to the broth microdilution method of the Clinical and Laboratory Standards Institute (15).

**Total RNA extraction and qRT-PCR.** Plugs from fresh cultures of five *T. rubrum* strains (CBS118892, TIMM20083, TIMM20084, TIMM20086, and TIMM20087) and seven *A. vanbreuseghemii* strains (1062Av1401, Av-FRT-1-3, AvS38A, AvS714J6, Tr-FRT-52-9, Tr-T31C, and Tr-T719J) grown on SDA were inoculated in about 15 ml of RPMI 1640 broth and cultivated at 28°C on a rotary shaker at 200 rpm. After 3 days, the growing mycelia from each strain were collected, frozen, and ground under liquid nitrogen with a Multi-Beads shocker (Yasui Kikai) at 1,800 rpm for 10 s, which was repeated 3 times. Total RNA was extracted using an RNeasy Plant minikit (Qiagen) and was treated with DNase I (Invitrogen). First-strand cDNA was synthesized using a high-capacity RNA-to-cDNA kit (Applied Biosystems). The quantitative real-time reverse transcription-PCR (qRT-PCR) analysis was performed using Fast SYBR green PCR master mix on an ABI PRISM 7500 Fast real-time PCR system (Applied Biosystems) under standard conditions, according to the manufacturer's recommendations. Two sets of primers were used, one to amplify *SQLE* alleles derived from *A. vanbreuseghemii* (qRT\_erg1\_2-F and qRT\_erg1\_2-R) and the other to amplify *SQLE* alleles derived from *T. rubrum* [qRT\_erg(Tr)1\_2-F and qRT\_erg1\_2-R] (Table 4). Dissociation curves of the qPCR-amplified products were plotted to confirm the absence of nonspecific products or primer dimers. Normalization was done to the 18S rRNA gene using two primers, 18S-1-F and 18S-1-R (33), and relative quantification of gene expression was calculated according to the  $2^{-\Delta\Delta C_T}$  (where  $C_T$  is threshold cycle) method. Expression levels of *SQLE* genes examined in six *A. vanbreuseghemii* transformants and four *T. rubrum* clinical isolates are indicated as relative fold changes compared to levels in the *A. vanbreuseghemii* parent strain 1062Av1401 or the wild-type *T. rubrum* strain CBS118892, respectively. Statistical significance of *SQLE* gene expression levels among strains was evaluated using Student's *t* test.

**Nucleotide sequence accession number.** The nucleotide sequence of the *A. vanbreuseghemii* *SQLE* (AvSQLE) locus containing the ORF was deposited in the GenBank under accession number [KU242352](https://doi.org/10.1128/AAC.00115-17).

## SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at <https://doi.org/10.1128/AAC.00115-17>.

**SUPPLEMENTAL FILE 1**, PDF file, 0.3 MB.

## ACKNOWLEDGMENTS

We thank Junko Ito (Chiba University Medical Mycology Research Center, Chiba, Japan) for technical support in the drug susceptibility tests of dermatophyte strains by the microdilution method of the Clinical and Laboratory Standards Institute (CLSI M38-A2).

This study was partly supported by the National BioResource Project—Pathogenic Microbes in Japan and the Joint Usage/Research Program of the Medical Mycology Research Center, Chiba University (grant number 16-26).

## REFERENCES

1. Monod M, Jaccoud S, Zaugg C, Léchenne B, Baudraz F, Panizzon R. 2002. Survey of dermatophyte infections in the Lausanne area, Switzerland. *Dermatology* 205:201–203. <https://doi.org/10.1159/000063913>.
2. Reiss E, Shadomy HJ, Lyon GM. 2011. *Fundamental medical mycology*, p 527–565. Wiley-Blackwell, Hoboken, NJ.
3. Reiss E, Shadomy HJ, Lyon GM. 2011. *Fundamental medical mycology*, p 75–105. Wiley-Blackwell, Hoboken, NJ.
4. Odds FC, Brown AJ, Gow NA. 2003. Antifungal agents: mechanisms of action. *Trends Microbiol* 11:272–279. [https://doi.org/10.1016/S0966-842X\(03\)00117-3](https://doi.org/10.1016/S0966-842X(03)00117-3).

5. Takami T, Fang Y, Zhou X, Jaiseng W, Ma Y, Kuno T. 2012. A genetic and pharmacological analysis of isoprenoid pathway by LC-MS/MS in fission yeast. *PLoS One* 7:e49004. <https://doi.org/10.1371/journal.pone.0049004>.
6. Mukherjee PK, Leidich SD, Isham N, Leitner I, Ryder NS, Ghannoum MA. 2003. Clinical *Trichophyton rubrum* strain exhibiting primary resistance to terbinafine. *Antimicrob Agents Chemother* 47:82–86. <https://doi.org/10.1128/AAC.47.1.82-86.2003>.
7. Favre B, Ghannoum MA, Ryder NS. 2004. Biochemical characterization of terbinafine-resistant *Trichophyton rubrum* isolates. *Med Mycol* 42:525–529. <https://doi.org/10.1080/13693780410001661482>.
8. Osborne CS, Leitner I, Favre B, Ryder NS. 2005. Amino acid substitution in *Trichophyton rubrum* squalene epoxidase associated with resistance to terbinafine. *Antimicrob Agents Chemother* 49:2840–2844. <https://doi.org/10.1128/AAC.49.7.2840-2844.2005>.
9. Osborne CS, Leitner I, Hofbauer B, Fielding CA, Favre B, Ryder NS. 2006. Biological, biochemical, and molecular characterization of a new clinical *Trichophyton rubrum* isolate resistant to terbinafine. *Antimicrob Agents Chemother* 50:2234–2236. <https://doi.org/10.1128/AAC.01600-05>.
10. Osborne CS, Hofbauer B, Favre B, Ryder NS. 2003. *In vitro* analysis of the ability of *Trichophyton rubrum* to become resistant to terbinafine. *Antimicrob Agents Chemother* 47:3634–3636. <https://doi.org/10.1128/AAC.47.11.3634-3636.2003>.
11. Sanglard D, Kuchler K, Ischer F, Pagani JL, Monod M, Bille J. 1995. Mechanisms of resistance to azole antifungal agents in *Candida albicans* isolates from AIDS patients involve specific multidrug transporters. *Antimicrob Agents Chemother* 39:2378–2386. <https://doi.org/10.1128/AAC.39.11.2378>.
12. Sanglard D, Ischer F, Koymans L, Bille J. 1998. Amino acid substitutions in the cytochrome P-450 lanosterol 14 $\alpha$ -demethylase (CYP51A1) from azole-resistant *Candida albicans* clinical isolates contribute to resistance to azole antifungal agents. *Antimicrob Agents Chemother* 42:241–253. <https://doi.org/10.1093/jac/42.2.241>.
13. Morschhäuser J. 2010. Regulation of multidrug resistance in pathogenic fungi. *Fungal Genet Biol* 47:94–106. <https://doi.org/10.1016/j.fgb.2009.08.002>.
14. Alshahni MM, Yamada T. 2017. Genetic manipulations in dermatophytes. *Mycopathologia* 182:33–43. <https://doi.org/10.1007/s11046-016-0039-y>.
15. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard, 2nd ed. CLSI document M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
16. Leber R, Fuchsichler S, Klobučniková V, Schweighofer N, Pitters E, Wohlfarter K, Lederer M, Landl K, Ruckenstein C, Halapa I, Turnowsky F. 2003. Molecular mechanism of terbinafine resistance in *Saccharomyces cerevisiae*. *Antimicrob Agents Chemother* 47:3890–3900. <https://doi.org/10.1128/AAC.47.12.3890-3900.2003>.
17. Rocha EMF, Gardiner RE, Park S, Martinez-Rossi NM, Perlin DS. 2006. A Phe389Leu substitution in ErgA confers terbinafine resistance in *Aspergillus fumigatus*. *Antimicrob Agents Chemother* 50:2533–2536. <https://doi.org/10.1128/AAC.00187-06>.
18. Nowosielski M, Hoffmann M, Wyrwicz LS, Stepniak P, Plewczynski DM, Lazniewski M, Ginalski K, Rychlewski L. 2011. Detailed mechanism of squalene epoxidase inhibition by terbinafine. *J Chem Infect Model* 51:455–462. <https://doi.org/10.1021/ci100403b>.
19. Kelly SL, Lamb DC, Loeffler J, Einsele H, Kelly DE. 1999. The G464S amino acid substitution in *Candida albicans* sterol 14 $\alpha$ -demethylase causes fluconazole resistance in the clinic through reduced affinity. *Biochem Biophys Res Commun* 262:174–179. <https://doi.org/10.1006/bbrc.1999.1136>.
20. MacCallum DM, Coste A, Ischer F, Jacobsen MD, Odds FC, Sanglard D. 2010. Genetic dissection of azole resistance mechanisms in *Candida albicans* and their validation in a mouse model of disseminated infection. *Antimicrob Agents Chemother* 54:1476–1483. <https://doi.org/10.1128/AAC.01645-09>.
21. Fachin AL, Ferreira-Nozawa MS, Maccheroni W, Jr, Martinez-Ros si NM. 2006. Role of the ABC transporter TruMDR2 in terbinafine, 4-nitroquinoline N-oxide and etidimium bromide susceptibility in *Trichophyton rubrum*. *J Med Microbiol* 55:1093–1099. <https://doi.org/10.1099/jmm.0.46522-0>.
22. Takahata S, Kubota N, Takei-Masuda N, Yamada T, Maeda M, Alshahni MM, Abe S, Tabata Y, Maebashi K. 2016. Mechanism of action of ME1111, a novel antifungal agent for topical treatment of onychomycosis. *Antimicrob Agents Chemother* 60:873–880. <https://doi.org/10.1128/AAC.01790-15>.
23. Martinez DA, Oliver BG, Gräser Y, Goldberg JM, Li W, Martinez-Rossi NM, Monod M, Shelest E, Barton RC, Birch E, Brakhage AA, Chen Z, Gurr SJ, Heiman D, Heitman J, Kosti I, Rossi A, Saif S, Samalova M, Saunders CW, Shea T, Summerbell RC, Xu J, Young S, Zeng Q, Birren BW, Cuomo CA, White TC. 2012. Comparative genome analysis of *Trichophyton rubrum* and related dermatophytes reveals candidate genes involved in infection. *mBio* 3:e00259-12. <https://doi.org/10.1128/mBio.00259-12>.
24. Millon L, Manteaux A, Reboux G, Drobacheff C, Monod M, Barale T, Michel-Briand Y. 1994. Fluconazole-resistant recurrent oral candidiasis in human immunodeficiency virus-positive patients: persistence of *Candida albicans* strains with the same genotype. *J Clin Microbiol* 32:1115–1118.
25. Yamada Y, Maeda M, Alshahni MM, Monod M, Staib P, Yamada T. 2014. Flippase (FLP) recombinase-mediated marker recycling in the dermatophyte *Arthroderma vanbreuseghemii*. *Microbiology* 160:2122–2135. <https://doi.org/10.1099/mic.0.076562-0>.
26. Mimori T, Ohosone Y, Hama N, Suwa A, Akizuki M, Homma M, Griffith AJ, Hardin JA. 1990. Isolation and characterization of cDNA encoding the 80-kDa subunit protein of the human autoantigen Ku (p70/p80) recognized by autoantibodies from patients with scleroderma-polymyositis overlap syndrome. *Proc Natl Acad Sci U S A* 87:1777–1781. <https://doi.org/10.1073/pnas.87.5.1777>.
27. Uchida K, Tanaka T, Yamaguchi H. 2003. Achievement of complete mycological cure by topical antifungal agent NND-502 in guinea pig model of tinea pedis. *Microbiol Immunol* 47:143–146. <https://doi.org/10.1111/j.1348-0421.2003.tb02797.x>.
28. Hood EE, Gelvin SB, Melchers LS, Hoekema A. 1993. New *Agrobacterium* helper plasmids for gene transfer to plants. *Transgenic Res* 2:208–218. <https://doi.org/10.1007/BF01977351>.
29. Yamada T, Makimura K, Satoh K, Umeda Y, Ishihara Y, Abe S. 2009. *Agrobacterium tumefaciens*-mediated transformation of the dermatophyte, *Trichophyton mentagrophytes*: an efficient tool for gene transfer. *Med Mycol* 47:485–494. <https://doi.org/10.1080/13693780802322240>.
30. Mock M, Monod M, Baudraz-Rosselet F, Panizzon RG. 1998. Tinea capitis dermatophytes: susceptibility to antifungal drugs tested *in vitro* and *in vivo*. *Dermatology* 197:361–367. <https://doi.org/10.1159/000018032>.
31. Verrier J, Pronina M, Peter C, Bontems O, Fratti M, Salamin K, Schürch S, Gindro K, Wolfender JL, Harshman K, Monod M. 2012. Identification of infectious agents in onychomycoses by PCR-terminal restriction fragment length polymorphism. *J Clin Microbiol* 50:553–561. <https://doi.org/10.1128/JCM.05164-11>.
32. Jackson CJ, Barton RC, Kelly SL, Evans EGV. 2000. Strain identification of *Trichophyton rubrum* by specific amplification of subrepeat elements in the ribosomal DNA nontranscribed spacer. *J Clin Microbiol* 38:4527–4534.
33. Diao Y, Zhao R, Deng X, Leng W, Peng J, Jin Q. 2009. Transcriptional profiles of *Trichophyton rubrum* in response to itraconazole. *Med Mycol* 47:237–247. <https://doi.org/10.1080/13693780802227308>.
34. Iwata A, Alshahni MM, Nishiyama Y, Makimura K, Abe S, Yamada T. 2012. Development of a tightly regulatable copper-mediated gene switch system in dermatophytes. *Appl Environ Microbiol* 78:5204–5211. <https://doi.org/10.1128/AEM.00464-12>.
35. Kopke K, Hoff B, Kück U. 2010. Application of the *Saccharomyces cerevisiae* FLP/FRT recombination system in filamentous fungi for marker recycling and construction of knockout strains devoid of heterologous genes. *Appl Environ Microbiol* 76:4664–4674. <https://doi.org/10.1128/AEM.00670-10>.
36. Alshahni MM, Yamada T, Makimura K, Takatori K, Sawada T. 2010. Nourseothricin acetyltransferase: a new dominant selectable marker for the dermatophyte *Trichophyton mentagrophytes*. *Med Mycol* 48:665–668. <https://doi.org/10.3109/13693780903330555>.
37. Zhang A, Lu P, Dahl-Roshak AM, Paresse PS, Kennedy S, Tkacz JS, An Z. 2003. Efficient disruption of a polyketide synthase gene (pks1) required for melanin synthesis through *Agrobacterium*-mediated transformation of *Glarea lozoyensis*. *Mol Genet Genomics* 268:645–655.